Journal
CHEMISTRY & BIOLOGY
Volume 15, Issue 3, Pages 234-245Publisher
CELL PRESS
DOI: 10.1016/j.chembiol.2008.02.010
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA097061, R01 CA097061-03, R01 CA097061-06, R01 CA097061-05A1, R01CA097061, R01 CA097061-01, R01 CA097061-02, R01 CA097061-04] Funding Source: Medline
Ask authors/readers for more resources
We screened small molecules to identify two compounds, which we named RSL3 and RSL5, that have increased lethality in the presence of oncogenic RAS. Counter screening with biologically active compounds defined aspects of the mechanism of action for RSL3 and RSL5, such as a nonapoptotic, M EK-dependent, and iron-dependent oxidative cell death. Erastin, a previously reported compound with RAS-selective lethality, showed similar properties. RNA interference experiments targeting voltage-dependent anion channel 3 (VDAC3), a target of erastin, demonstrated that RSL5 is a scaffold that acts through VDACs to activate the observed pathway. RSL3 activated a similar death mechanism but in a VDAC-independent manner. We found that cells transformed with oncogenic RAS have increased iron content relative to their normal cell counterparts through upregulation of transferrin receptor 1 and downregulation of ferritin heavy chain 1 and ferritin light chain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available